Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access

Executive Summary

Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested

You may also be interested in...



GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs

GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005

GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs

GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005

Ivax breath-activated HFA albuterol “approvable”

Ivax' breath-activated hydrofluoroalkane-propelled albuterol gets "approvable" letter from FDA, the company announces July 7. Ivax markets the breath-activated device as Easi-Breathe in Europe. Members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested delaying a chlorofluorocarbon ban to allow time for Ivax' and Sepracor's Xopenex HFA (levalbuterol) products to reach market (1"The Pink Sheet" June 21, 2004, p. 42)...

Related Content

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel